REG - Craneware plc - FY26 Trading Update

RNS Number : 8784K Craneware plc 03 July 2026  

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a Regulatory Information Service, this information is considered to be in the public domain.

03 July 2026

Craneware plc

("Craneware" or the "Company")

FY26 Trading Update

Craneware (AIM: CRW.L), a leader in healthcare financial performance solutions, provides the following update on trading for the financial year ended 30 June 2026 ("FY26").

The Board expects the Group's FY26 financial performance to be below market expectations, with revenue of US$205-$208 million and Adjusted EBITDA of US$65-$67 million, both broadly in line with FY25. This change results from the timing of eligible 340B activity and the deferral of a small number of significant enterprise contracts, which are now expected to contribute during FY27. The final reported outcome remains subject to confirmation of eligible 340B activity recognised before the financial year end.

Customer retention, customer demand and cash generation have remained strong throughout the year. Trading in the final weeks of FY26 was materially impacted by a slower than anticipated conversion of identified 340B opportunities into recognised revenue. Craneware continues to identify substantial opportunities for hospitals to optimise their 340B programs; with outstanding 340B qualifying drug purchases in the region of $500m, however, the pace at which those opportunities translated into eligible drug purchases slowed significantly as pharmaceutical manufacturers further expanded and operationalised restrictions on the supply of certain 340B-priced medicines.

The Group recognises a significant proportion of this revenue upon the customer receiving the benefit from these eligible 340B drugs, rather than at the point opportunities are identified. The financial impact of this reduced conversion only became apparent once the actual amount of 340B drugs shipped to the hospitals before year end became clear.

The Board believes that these factors reflect a short-term timing impact to the FY26 results. Looking ahead, customer demand is increasingly extending beyond software and analytics towards technology-enabled operational transformation that helps healthcare providers realise the opportunities identified by the Group's platform. Craneware has been developing these capabilities over the last three years and they now represent a meaningful and growing component of the Group's offering. This reinforces, rather than diminishes, the long-term strategic importance of Craneware's platform within the evolving US healthcare ecosystem.

The combination of Craneware's trusted data, technology, AI enabled workflows and people, collectively expands the Group's technology-enabled operational capabilities, positioning Craneware to support customers in navigating an increasingly complex healthcare environment and realise greater financial value from their operations.

The Board will provide a further update with the announcement of the Group's full year results in September 2026.

Keith Neilson, CEO of Craneware plc, commented,

"Naturally we are disappointed not to have delivered the growth that we expected in FY26. While the short-term complexity in the pharmacy market has impacted the year, the long-term opportunity remains intact.

"This reinforces our strategy of expanding beyond software and analytics into technology-enabled operational transformation that helps customers realise the opportunities identified by the Group's platform, and this is a continuing area of focus for our innovation efforts. We believe this strengthens both our customer relationships and our long-term growth opportunity, as healthcare providers increasingly seek trusted partners capable of combining data, workflow automation and operational expertise to deliver measurable financial outcomes. Our role is evolving from helping customers identify opportunity to helping them realise it.

"We continue to benefit from high levels of customer retention and cash generation, providing us with a strong financial foundation to execute on our strategy."

For further information, please contact:

About Craneware

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster - that simplify the complexities of healthcare finance and operations. What sets us apart is our unique combination of deep healthcare expertise and engineering excellence, positioning us as a strategic partner rather than just a technology provider. The Craneware Group empowers healthcare organizations to achieve sustainable financial success while delivering better outcomes for the communities they serve - today and in the future. Together, we are transforming the business of healthcare.

Learn more at www.thecranewaregroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  TSTAKBBBDBKBCOK